Scientific Advisory Board

B%2520Lee%25202014_edited_edited.jpg

Brendan Lee, M.D., Ph.D.

Chair & Professor

Department of Molecular and Human Genetics
Baylor College of Medicine

Fellow 

American Association for the Advancement of Science (AAAS)

National Academy of Medicine

“The bioinformatics approach by Fresh Wind Biotechnologies has the potential to rapidly identify targets for enhancing both the specificity and broad application of immunotherapy applications”

Heslop%252C%2520Helen_03%2520September%25202020_edited_edited.jpg

Helen Heslop, MD, DSc (Hon)

Director

Center for Cell and Gene Therapy

Professor

Departments of Medicine and Pediatrics
Section of Hematology-Oncology

Baylor College of Medicine

Fellow

National Academy of Medicine 

“Over the past few years it has become apparent that immunotherapy is now a major treatment modality for cancer.  Because of its precision, memory  and ability to evolve it has the potential for even broader application”

lu_shun_edited_edited_edited.jpg

Shun Lu, M.D., Ph.D.

Professor

Shanghai Chest Hospital

Jiao Tong University

Chief

Shanghai Lung Cancer Center

"Immunotherapy, especially neoantigen discovery and cellular therapies are entering a revolutionary phase for solid tumor treatment. As a clinical oncologist, this is exciting to witness and act as a catalyst for the development in Fresh Wind Biotech.  It is a great honor to work with this leading team with extensive scientific research and industrialization experiences."

 

Strategic Advisory Board

Feldman, Steven_edited_edited_edited_edited.jpg

Steven A. Feldman, Ph.D.

Site Head and Scientific Director

Stanford’s Laboratory of Cell and Gene Medicine
Stanford GMP Facility

Dr. Feldman leads process development and manufacturing efforts at Stanford’s GMP Facility to ensure safe administration of cell therapy products in support of Stanford Investigator-Initiated and Industry-sponsored clinical trials. His research efforts are focused on the directed modulation of cellular pathways to prevent T cell exhaustion and development of novel cell therapy manufacturing platforms. Previously, Dr. Feldman was a member of the Surgery Branch, National Cancer Institute (NCI) where he was a leader in the effort to develop mutation-reactive TIL-based cell therapies for patients with breast cancer.

DSC_5831_edited_edited_edited.jpg

Karim Iskander, Ph.D.

VP & Head of Medical Affairs

BioMarin Pharmaceuticals

Dr. Iskander has more than 20 years of oncology experience, including 15 years of industry experience. He currently leads BioMarin’s medical affairs function in US and Canada across four therapeutic areas.  Prior to that, he was the Executive Medical Director and global Hematology Head at Amgen, where he served on the Hematology and Oncology Franchise Steering committee accountable for defining the strategy and the review and endorsement of all development, regulatory and commercialization activities across solid and liquid tumors. Before joining Amgen, Karim had several roles with increasing responsibilities at Onyx and Cephalon including leading the medical directors’ function and medical research operations at Onyx. He also practiced oncology pharmacy at MD Anderson Cancer Center.